published meta-analysis   sensitivity analysis   studies

chloroquine and derivatives in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsHYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] RECOVERY, 2020 1.09 [0.97; 1.23] SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59] 1.08[0.95; 1.23]HYDRA (Hernandez-Cardenas), 2021, RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 2020311%6,783moderatenot evaluable deathsdetailed resultsAbd-Elsalam, 2020 1.21 [0.36; 4.12] Chen, 2020 0.56 [0.01; 30.20] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.47 [0.48; 4.52] Gonzalez_HCQ, 2020 0.33 [0.06; 1.78] HC-nCoV (Shanghai), 2020 1.00 [0.02; 53.89] HYCOVID, 2020 0.54 [0.21; 1.40] HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] NO COVID-19 (Lyngbakken), 2020 0.96 [0.06; 15.78] ORCHID, 2020 1.07 [0.54; 2.11] RECOVERY, 2020 1.09 [0.97; 1.23] SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59] TEACH, 2020 1.07 [0.34; 3.37] 1.07[0.97; 1.19]Abd-Elsalam, 2020, Chen, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, Gonzalez_HCQ, 2020, HC-nCoV (Shanghai), 2020, HYCOVID, 2020, HYDRA (Hernandez-Cardenas), 2021, NO COVID-19 (Lyngbakken), 2020, ORCHID, 2020, RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 2020, TEACH, 2020120%8,349moderatelow deaths (time to event analysis only)detailed resultsHYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] RECOVERY, 2020 1.09 [0.97; 1.23] SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59] 1.08[0.95; 1.23]HYDRA (Hernandez-Cardenas), 2021, RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 2020311%6,783moderatenot evaluable clinical deteriorationdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.21 [0.69; 2.12] TEACH, 2020 1.80 [0.62; 5.21] 1.32[0.80; 2.16]Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, TEACH, 202020%460moderatenot evaluable clinical improvementdetailed resultsORCHID, 2020 1.02 [0.73; 1.42] 1.02[0.73; 1.42]ORCHID, 202010%479lownot evaluable clinical improvement (14-day)detailed resultsChen, 2020 0.56 [0.13; 2.48] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.83 [0.47; 1.44] ORCHID, 2020 1.02 [0.73; 1.42] 0.95[0.71; 1.25]Chen, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, ORCHID, 202030%960moderatenot evaluable clinical improvement (28-day)detailed resultsORCHID, 2020 0.97 [0.69; 1.37] 0.97[0.69; 1.37]ORCHID, 202010%479lownot evaluable clinical improvement (7-day)detailed resultsORCHID, 2020 1.16 [0.84; 1.61] 1.16[0.84; 1.61]ORCHID, 202010%479lownot evaluable clinical improvement (time to event analysis only)detailed resultsHYDRA (Hernandez-Cardenas), 2021 1.05 [0.74; 1.48] ORCHID, 2020 0.97 [0.69; 1.36] 1.01[0.79; 1.28]HYDRA (Hernandez-Cardenas), 2021, ORCHID, 202020%693moderatenot evaluable death or ventilationdetailed resultsGonzalez_HCQ, 2020 0.69 [0.22; 2.21] HYCOVID, 2020 1.12 [0.45; 2.79] ORCHID, 2020 1.13 [0.60; 2.13] RECOVERY, 2020 1.14 [1.03; 1.27] SOLIDARITY (WHO study) HCQ, 2020 1.11 [0.87; 1.42] 1.13[1.03; 1.24]Gonzalez_HCQ, 2020, HYCOVID, 2020, ORCHID, 2020, RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 202050%6,570moderatenot evaluable hospital dischargedetailed resultsGonzalez_HCQ, 2020 1.38 [0.46; 4.16] HYDRA (Hernandez-Cardenas), 2021 1.01 [0.72; 1.42] 1.04[0.75; 1.44]Gonzalez_HCQ, 2020, HYDRA (Hernandez-Cardenas), 202120%284moderatenot evaluable viral clearance detailed resultsHC-nCoV (Shanghai), 2020 0.46 [0.04; 5.75] 0.46[0.04; 5.75]HC-nCoV (Shanghai), 202010%30moderatenot evaluable viral clearance by day 14detailed resultsChen, 2020 1.42 [0.26; 7.76] 1.42[0.26; 7.76]Chen, 202010%33moderatenot evaluable ICU admissiondetailed resultsAbd-Elsalam, 2020 0.83 [0.35; 1.95] 0.83[0.35; 1.95]Abd-Elsalam, 202010%194moderatenot evaluable off oxygenationdetailed resultsHYDRA (Hernandez-Cardenas), 2021 0.98 [0.64; 1.51] 0.98[0.64; 1.51]HYDRA (Hernandez-Cardenas), 202110%214moderatenot evaluable cardiac arrestdetailed resultsSOLIDARITY (WHO study) HCQ, 2020 1.92 [0.35; 10.49] 1.92[0.35; 10.49]SOLIDARITY (WHO study) HCQ, 202010%1,853moderatenot evaluable serious adverse eventsdetailed resultsORCHID, 2020 1.26 [0.56; 2.84] 1.26[0.56; 2.84]ORCHID, 202010%479lownot evaluable adverse eventsdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.88 [0.29; 2.65] HC-nCoV (Shanghai), 2020 1.00 [0.02; 53.89] ORCHID, 2020 1.42 [0.87; 2.34] RECOVERY, 2020 1.36 [0.98; 1.90] TEACH, 2020 1.16 [0.55; 2.42] 1.32[1.03; 1.70]Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, HC-nCoV (Shanghai), 2020, ORCHID, 2020, RECOVERY, 2020, TEACH, 202050%5,685moderatenot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2021-06-19 21:00 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 508,656,657,832 - roots T: 290